No Data
A-shares closing commentary: The Shanghai Composite Index showed a V-shaped rebound, with over 3,200 stocks declining, while Siasun Robot&Automation and e-commerce stocks led the gains.
The total Trade is 1.26 trillion yuan, an increase of 197.8 billion yuan compared to the previous trading day.
Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): The crystal eye artificial lens has been approved for listing through the special review procedure for Innovative Medical Management.
On January 7, Gelonghui reported that Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) announced that its "artificial crystalline lens for phakic eyes" has recently been approved for registration by the National Medical Products Administration through a special review for Innovative Medical Management medical instruments. The artificial crystalline lens for phakic eyes is a refractive artificial lens, and this product is based on innovative balanced acrylic material, featuring a zero spherical aberration design with a large optical zone and a double concave stabilizing arch height design. Once implanted in the eye, it can serve as a refractive component, effectively reducing/correcting myopia and providing patients with high-quality postoperative visual acuity.
Beijing Balance Medical Technology Co., Ltd. (688198.SH): The pulmonary artery valve and delivery system have entered the special review process for Innovative Medical Management.
On January 3, Longhu announced that Beijing Balance Medical Technology Co., Ltd. (688198.SH) has received approval from the Medical Device Technical Evaluation Center of the National Medical Products Administration for the self-developed first all-comer interventional pulmonary valve and delivery system, entering the special review procedure for innovative medical instruments. The company's interventional pulmonary valve and delivery system is designed for patients who need catheter artificial biological pulmonary valve replacement after surgical right ventricle outflow tract repair and reconstruction due to complex congenital heart disease. This product is the third interventional valve product of the company to enter the special review procedure for innovative medical instruments, and it also manages the full lifecycle of pulmonary valve patients.
Sinolink: Initiates a "Shareholding" rating for LIFETECH SCI with a Target Price of 1.8 Hong Kong dollars.
Sinolink released a research report stating that it has initiated coverage of LIFETECH SCI (01302) with a "Shareholding" rating, Bullish on the company's long-term development in the field of cardiovascular and cerebrovascular intervention. The company is expected to have revenue of 1.256/1.687/2.076 billion yuan from 2024 to 2026, with a year-on-year change of -1%/+34%/+23%; Net income of 0.294/0.373/0.466 billion yuan, with a year-on-year change of +12%/+27%/+25%. The Target Price is HKD 1.8 per share. The main points from Sinolink are as follows: A medical instruments company with a rich pipeline, focused on cardiovascular and cerebrovascular intervention research and development. The company adheres to
A-share midday review: Shanghai index down 0.72%, nearly 4,300 stocks in the red, CSI Consumer 360 index continues to adjust.
By the end of the midday session, the Shanghai Composite Index fell by 0.72% to 3357.82 points, the Shenzhen Component Index dropped by 0.33%, and the Chinext Price Index decreased by 0.36%.
Optimistic Investors Push Innovative Medical Management Co.,Ltd. (SZSE:002173) Shares Up 37% But Growth Is Lacking
More Unpleasant Surprises Could Be In Store For Shenzhen Sea Star Technology Co., Ltd.'s (SZSE:002137) Shares After Tumbling 27%
